Roxanne Lagano Sells 326 Shares of Zoetis Inc. (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Roxanne Lagano also recently made the following trade(s):

• On Tuesday, February 11th, Roxanne Lagano sold 326 shares of Zoetis stock. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68.

Zoetis Stock Performance

Shares of Zoetis stock opened at $161.74 on Thursday. The firm has a market capitalization of $72.43 billion, a P/E ratio of 29.57, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The firm’s 50 day moving average is $166.92 and its two-hundred day moving average is $176.44. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Institutional Investors Weigh In On Zoetis

Several large investors have recently modified their holdings of ZTS. Howard Capital Management Group LLC lifted its holdings in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth $33,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Finally, Legacy Capital Wealth Partners LLC lifted its holdings in shares of Zoetis by 82.2% during the third quarter. Legacy Capital Wealth Partners LLC now owns 3,211 shares of the company’s stock worth $627,000 after purchasing an additional 1,449 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.